Population, Policy and Practice Research and Teaching Department, University College London Great Ormond Street Institute of Child Health, London, WC1N 1EH, UK.
Ulverscroft Vision Research Group, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.
Pharmacoeconomics. 2024 Mar;42(3):275-299. doi: 10.1007/s40273-023-01311-5. Epub 2023 Nov 16.
Evidence on the socioeconomic burden associated with childhood visual impairment, severe visual impairment and blindness (VI/SVI/BL) is needed to inform economic evaluations of existing and emerging interventions aimed at protecting or improving vision. This study aimed to evaluate the quantity and quality of literature on resource use and/or costs associated with childhood VI/SVI/BL disorders.
PubMed, Web of Science (Ovid), the National Health Service (NHS) Economic Evaluation Database and grey literature were searched in November 2020. The PubMed search was rerun in February 2022. Original articles reporting unique estimates of resource use or cost data on conditions resulting in bilateral VI/SVI/BL were eligible for data extraction. Quality assessment (QA) was undertaken using the Drummond checklist adapted for cost-of-illness (COI) studies.
We identified 31 eligible articles, 27 from the peer-reviewed literature and four from the grey literature. Two reported on resource use, and 29 reported on costs. Cerebral visual impairment and optic nerve disorders were not examined in any included studies, whereas retinopathy of prematurity was the most frequently examined condition. The quality of studies varied, with economic evaluations having higher mean QA scores (82%) compared to COI studies (77%). Deficiencies in reporting were seen, particularly in the clinical definitions of conditions in economic evaluations and a lack of discounting and sensitivity analyses in COI studies.
There is sparse literature on resource use or costs associated with childhood visual impairment disorders. The first step in addressing this important evidence gap is to ensure core visual impairment outcomes are measured in future randomised control trials of interventions as well as cohort studies and are reported as a discrete health outcome.
需要有证据表明与儿童视力障碍、重度视力障碍和失明(VI/SVI/BL)相关的社会经济负担,以便为现有和新出现的旨在保护或改善视力的干预措施的经济评估提供信息。本研究旨在评估与儿童 VI/SVI/BL 疾病相关的资源利用和/或成本的文献数量和质量。
2020 年 11 月,在 PubMed、Web of Science(Ovid)、英国国家卫生服务体系(NHS)经济评估数据库和灰色文献中进行了检索。2022 年 2 月重新进行了 PubMed 检索。符合条件的原始文章需报告有关导致双眼 VI/SVI/BL 的疾病的资源利用或成本数据的独特估计值。使用 Drummond 清单(适用于疾病成本研究)进行质量评估(QA)。
我们确定了 31 篇符合条件的文章,其中 27 篇来自同行评议文献,4 篇来自灰色文献。有 2 篇报告了资源利用情况,29 篇报告了成本情况。没有研究检查脑性视觉障碍和视神经疾病,而早产儿视网膜病变是最常检查的疾病。研究质量参差不齐,经济评估的平均 QA 评分(82%)高于疾病成本研究(77%)。在经济评估中,尤其是在临床疾病定义方面,以及在疾病成本研究中缺乏贴现和敏感性分析方面,报告存在缺陷。
与儿童视力障碍疾病相关的资源利用或成本的文献很少。解决这一重要证据差距的第一步是确保未来干预措施的随机对照试验以及队列研究中测量和报告核心视力障碍结局,并将其作为一个离散的健康结局。